SCHEMBL8212669

SCHEMBL8212669

Nc1ccc(NC(=O)c2cc(O)ccc2Cl)c(Br)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
HSD17B10 Q99714 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RAB9A P51151 2/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GFER P55789 1/20 0.42
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
RECQL P46063 1/20 0.41
PKM P14618 1/20 0.41
MAPK1 P28482 1/20 0.41
ABL1 P00519 1/20 0.41
TSHR P16473 1/20 0.41
RIN1 Q13671 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8205901 0.89 MAPT (0.57) MAPTKMT2AMEN1HSD17B10SMN1; SMN2
SCHEMBL8053240 0.80 RORC (0.61) MAPTKMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL8213832 0.76 HSD17B10 (0.53) MAPTKMT2AMEN1HSD17B10SMN1; SMN2
SCHEMBL28582515 0.76 ALDH1A1 (0.67) MAPTKMT2AMEN1HSD17B10SMN1; SMN2
SCHEMBL8212323 0.74 RORC (0.53) MAPTKMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL18147101 0.73 MEN1 (0.52) MAPTKMT2AMEN1HSD17B10SMN1; SMN2
SCHEMBL8216234 0.73 JAK2 (0.49) MAPTKMT2AMEN1HSD17B10SMN1; SMN2
SCHEMBL11573737 0.73 CA1 (0.63) MAPTHSD17B10SMN1; SMN2RAB9AKDM4E
SCHEMBL18146154 0.73 CYP1A2 (0.68) MAPTKMT2AMEN1HSD17B10SMN1; SMN2
SCHEMBL10597000 0.72 RAB9A (0.59) MAPTKMT2AMEN1HSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008021088-A2 SALICYLANILIDES ENHANCE ORAL DELIVERY OF THERAPEUTIC PEPTIDES THE REGENTS OF THE UNIVERSITY OF CALIFORNINA (US) 2008-02-21 WO disclosed